News | November 23, 2024
Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
The product will be manufactured at Lupin’s Somerset facility in the US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This product will be manufactured at Lupin’s Nagpur facility in India
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Subscribe To Our Newsletter & Stay Updated
